ICON Public Company (ICLR) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
28 Oct, 2026Executive summary
Record net business wins reached $3.15B, with 1.56x net book-to-bill; closing backlog was $24.5B, up 4.8% sequentially.
Revenue was $2,024.8M; adjusted EBITDA margin rose 70 bps sequentially to 16.6%, and adjusted diluted EPS was $2.66.
Financial highlights
Q3 revenue declined 2.9% YoY, or 2.5% at constant currency; it was $2,024.8M versus $2,063M in Q2 2026 and $2,084M in Q3 2025.
Adjusted EBITDA was $336.9M, down 13.1% YoY; margin was 16.6%, versus 15.9% in Q2 2026 and 18.6% in Q3 2025.
GAAP net income was $122.1M and diluted EPS was $1.58; adjusted net income was $205.8M and adjusted diluted EPS was $2.66, versus $3.20 YoY.
9M revenue was $6,122.2M, down 0.3% YoY; adjusted EBITDA was $981.9M, down 18.4%. Adjusted diluted EPS was $7.72 versus $9.99 YoY.
GAAP operating income was $199M, or 10% of revenue; adjusted gross margin was 24.7%, up 90 bps sequentially.
Outlook and guidance
FY2026 revenue guidance increased to $8,100M–$8,200M from $7,850M–$8,150M, primarily reflecting higher pass-through activity.
FY2026 adjusted diluted EPS guidance is $10.35–$10.65, narrowed from $10.00–$11.00; it is non-GAAP and unreconciled due to uncertainty in forecasting certain GAAP items.
FY26 adjusted EBITDA margin is expected at 16.0%–16.5%, partly dependent on Q4 pass-through activity; adjusted effective tax rate is expected near 17%.
Management described mid-single-digit 2027 revenue growth and higher-single-digit earnings growth as possible, not formal guidance; formal guidance is due with Q4 results.
Latest events from ICON Public Company
- FY23 growth, $22.8bn backlog, and reaffirmed FY24 guidance.ICLR
Q4 2023 - Q2 2026 saw $2,063.5m revenue, 15.9% EBITDA margin, and strong bookings amid margin pressure.ICLR
Q2 2026 - Leadership transition and strategic focus on biotech, automation, and growth drive optimism.ICLR
Baird Global Healthcare Conference 2025 - Global regulators are advancing frameworks to include pregnant individuals in clinical trials.ICLR
Status Update - Q1 2026 revenue rose 0.9% to $2,034m, with strong bookings and reaffirmed guidance.ICLR
Q1 2026 - 2025 revenue and EPS fell after restatements; 2026 targets margin recovery and growth.ICLR
Q4 2025 - Q2 2024 saw strong growth, higher EPS, record backlog, and upgraded full-year guidance.ICLR
Q2 2024 - Growth targets of 7%-10% hinge on innovation, automation, and expanded pharma partnerships.ICLR
Jefferies 2024 Global Healthcare Conference - Revenue fell 4.3% in Q1 2025 as cancellations and COVID trial removals pressured outlook.ICLR
Q1 2025